Ligand id: 7485

Name: pegvisomant

No information available.
Summary of Clinical Use
Approved to treat acromegaly which has not been controlled by other interventions (eg surgery, radiation therapy or somatostatin treatment).
Mechanism Of Action and Pharmacodynamic Effects
Pegvisomant inhibits the ability of endogenous growth hormone to interact with the growth hormone receptor, the aim of which is to normalize serum IGF-I levels in acromegalic patients [1].
External links